Tony Berberabe, MPH

Phase 3 findings from the CLL12 trial support a watch-and-wait approach over systemic treatment with ibrutinib for patients with asymptomatic early-stage chronic lymphocytic leukemia.

Pembrolizumab inspired a 70% risk reduction in women with mismatch repair–deficient advanced endometrial cancer and a 46% risk reduction in patients with mismatch repair–proficient disease.

Findings from the phase 3 SUNLIGHT study showed that adding bevacizumab to trifluridine/tipiracil boosted overall survival in metastatic colorectal cancer.

Investigators reported that mitomycin gel was not associated with decrements in urinary symptoms, bloating and flatulence, or malaise, and that sexual function only mildly worsened.

The CD40 agonist sotigalimab in combination with pembrolizumab yielded promising outcomes in patients with unresectable stage III or IV metastatic melanoma.

While survival rates in T-cell acute lymphoblastic leukemia remain around 90%, researchers are optimistic that the use of targeted therapies and immunotherapies will continue to improve treatment options.

Treating patients with relapsed/refractory multiple myeloma with Talquetamab at RP2D elicits high clinical response rate.

Pediatric precision oncology in a real-world, multinational setting is feasible. For the subgroup of children with very high priority level targets, the INFORM registry provided therapeutic opportunities and new diagnostic information.

For men with positive needle biopsy for prostate cancer, active surveillance (AS) did not negatively impact their quality-of-life compared with men who had a negative prostate needle biopsy.

Although use of robotic surgery for prostate cancer has surpassed open surgical procedures, the impact of this approach on patient quality of life has not been well-studied.

When the United States Preventive Services Task Force (USPSTF) recommended against routine PSA screening for early detection of prostate cancer in May 2012, it caused a sea change in practice patterns among primary care physicians.

A new study has found that older, single white males with advanced bladder cancer have the highest suicide risk among those with other cancers of the male genitals and urinary system.

The continuing contentious debate about screening for prostate cancer remains top of mind among the public and lay press, but, Leonard G. Gomella, MD, told attendees at the 8th International Prostate Cancer Congress, the decision to screen or not to screen boiled down to "using common sense, shared decision making, and choosing the right patients to screen."

The first iteration of the American Society of Clinical Oncology's (ASCO's) endeavor to capture and harness big data, CancerLinQ, is scheduled for release in late 2015.

In May 2014, ASCO issued guidelines recommending the administration of adjuvant tamoxifen for 10 years in women with stage I-III hormone receptor (HR)-positive breast cancer, based on data from the collection of 5 clinical trials.

Even though breast cancer predominantly affects white women, breast cancer outcomes are worse among black women. But a new study suggests that enrollment in a federal program may help reduce racial disparities among these patients.

Does Medicare coverage for patients with cancer match up to what they actually want covered?

As the use of electronic patient portals grows, a new study examines the use of these portals by cancer patients, extending the doctor-patient relationship to new boundaries.

A pilot program initiated by UnitedHealthcare involving 5 oncology groups that focused on best treatment practices and health outcomes, rather than the number of drugs that oncologists prescribe, resulted in a 34% reduction in medical costs.

Patients with advanced cancer who received early specialized palliative care reported better quality of life and satisfaction, according to results from a randomized trial comparing such services with usual care published in The Lancet.

The number of cancer survivors in the United States is approaching 14 million, but that good news also means more attention must be paid to quality-of-life concerns for these individuals, as well as any long-term after effects of treatment.

As more cancer therapies move out of the infusion room and into the patient's home, ensuring that patients take these medications as prescribed poses an ongoing, multifaceted challenge for today's oncology practitioner.

Dermatologic adverse events (AEs) associated with anticancer therapies can be complex and are best managed with a proactive and holistic approach-one that takes into account not only the physical demands of the regimen itself, but also the many challenges that patients often face involving treatment adherence, quality of life, and psychosocial concerns.

Head and neck cancer patients who participated in a swallow preservation protocol (SPP) were less likely to suffer from the detrimental effects associated with dysphagia, a common complication associated with radiation therapy (RT) and chemoradiation therapy (CRT).

Many patients being treated with mTOR inhibitors experience dermatologic-related adverse events.